Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient

International Journal of STD and AIDS

Volumn 17, Issue 5, 2006, Pages 351-353

  Boumis, E ^a   Chinello, P ^a   Della Rocca, C ^b   Paglia, M G ^a   Proietti, M F ^a   Petrosillo, N ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Atypical disseminated leishmaniasis; HIV; Post kala azar dermal leishmaniasis

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; DIAMEDICS; LAMIVUDINE; MEGLUMINE ANTIMONATE; NELFINAVIR; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD EXAMINATION; CASE REPORT; CLINICAL FEATURE; DRUG TOLERANCE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEISHMANIASIS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEROLOGY; SKIN BIOPSY; SKIN LEISHMANIASIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIPROTOZOAL AGENTS; DIAGNOSIS, DIFFERENTIAL; HIV INFECTIONS; HUMANS; LEISHMANIA INFANTUM; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; TREATMENT OUTCOME;

EID: 33646347114     PISSN: 09564624     EISSN: 09564624     Source Type: Journal    
DOI: 10.1258/095646206776790132     Document Type: Article

References (20)

1. Zijlstra EE, Khalil EAG, Kager PA, et al. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis. Br J Dermatol 2000;143:136-43
2. Ramesh V, Mukherjee A. Post-kala-azar dermal leishmaniasis. Int J Dermatol 1995;34:85-91
3. Zijlstra EE, Musa AM, Khalil EAG, El Hassan IM, El Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003;3:87-98
4. Moral L. Post-kala-azar dermal leishmaniasis and Leishmania infantum. Br J Dermatol 1999;140:760
5. Ridolfo AL, Gervasoni C, Antinori S, et al. Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect 2000;40:199-202
6. Alarcon R, Garcia C, Dauden E, Guerra A, Vanaclocha F. Leishmaniasis cutanea post-kala-azar en un paciente con immunodeficiencia adquirida. Actas Dermo-Sif 1987;78:475-7
7. Rios-Buceta L, Buezo GF, Penas PF, et al. Post-kala-azar dermal leishmaniasis in a HIV-patient. Int J Dermatol 1996;35:303-4
8. Bittencourt A, Silva N, Straatmann A, et al. Post-kala-azar dermal leishmaniasis associated with AIDS. Braz J Infect Dis 2003;7:229-33
9. Gilad J, Borer A, Hallel-Halevy D, et al. Post-kala-azar dermal leishmaniasis manifesting after initiation of higly active anti-retroviral therapy in a patient with human immunodeficiency virus infection. Israel Med Assoc J 2001;3:451-2
10. Calza L, D'Antuono A, Marinacci G, et al. Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS. J Am Acad Dermatol 2004;50:461-5
11. Puig L, Pradinaud R. Leishmania and HIV co-infection: dermatological manifestations. Ann Trop Med Parasitol 2003;97(Suppl. 1):S107-14
12. Ritmeijer K, Veeken H, Melaku Y, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans Roy Soc Trop Med Hyg 2001;95:668-72
13. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998;351:228-30
14. Hashim FA, Khalil EAG, Ismael A, El-Hassan AM. Apparently successful treatment of two cases of post kalaazar dermal leishmaniasis with liposomal amphotericin B. Trans Roy Soc Trop Med Hyg 1995;89:440
15. Roustan G, Jimenez JA, Gutierrez-Solar B, et al. Post-kalaazar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: treatment with liposomal amphotericin B. Br J Dermatol 1999;140:760
16. Minodier P, Piarroux R, Gambarelli F, Joblet C, Dumon H. Rapid identification of causative species in patients with Old World leishmaniasis. J Clin Microbiol 1997;35:2551-5
17. Anonymous. Conclusions and recommendations of the IVth WHO joint meeting on Leishmania-HIV co-infections. Parasite 2001;8:376-9
18. Laguna F, Lopez-Velez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS 1999;13:1063-9
19. Thakur CP, Narain S, Kumar N, et al. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Ann Trop Med Parasitol 1997;91:611-16
20. Al-Jaser M, El-Yazigi A, Kojan M, Croft SL. Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis. Antimicrob Agents Chemother 1995;39:516-19